Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/162636
Title: Target product profile for a test for the early assessment of treatment efficacy in Chagas disease patients: An expert consensus.
Author: Alonso Padilla, Julio
Abril, Marcelo
Alarcón de Noya, Belkisyolé
Almeida, Igor Correia de
Angheben, Andrea
Araujo Jorge, Tania
Chatelain, Eric
Esteva, Mónica
Gascón i Brustenga, Joaquim
Grijalva, Mario J.
Guhl, Felipe
Hasslocher-Moreno, Alejandro M.
Lopez, Manuel C.
Luquetti, Alejandro
Noya, Oscar
Pinazo, María Jesús
Ramsey, Janine M.
Ribeiro, Isabela
Ruiz, Andres M.
Schijman, Alejandro G.
Sosa-Estani, Sergio
Thomas, M.Carmen
Torrico, Faustino
Zrein, Maan
Picado de Puig, Albert
Keywords: Malaltia de Chagas
Parasitologia mèdica
Chagas' disease
Medical parasitology
Issue Date: 23-Apr-2020
Publisher: PLoS
Abstract: Six to 7 million people are estimated to be infected by Trypanosoma cruzi, the parasite causing Chagas disease. Thirty to 40% of them, i.e., 1.8 to 2.4 million people, will suffer cardiac disorders and/or digestive clinical manifestations if they are not treated early during the course of the infection [1, 2]. However, only a small fraction of patients are properly diagnosed and treated [3]. Current clinical guidelines recommend treating T. cruzi–infected people if they are asymptomatic or present early symptoms of the disease (Table 1) [4, 5]. Benznidazole (BNZ) and nifurtimox (NFX) are the first-line antiparasitic treatments currently available, both with long administration regimens (60 days) that can produce adverse side effects [6–8]. Despite the fact they are not 100% effective in patients with chronic disease [9–12], they are the only drugs currently registered, and the benefits of their administration have been confirmed in several clinical studies. Currently, clinical trials with new compounds, using alternative regimens that aim to maintain efficacy whilst reducing toxicity, are ongoing and could lead to new therapeutic opportunities and/or policy change.
Note: Reproducció del document publicat a: http://dx.doi.org/ 10.1371/journal.pntd.0008035
It is part of: PLoS Neglected Tropical Diseases , 2020 , vol. 14 , num.4 , p.e0008035
URI: http://hdl.handle.net/2445/162636
Related resource: http://dx.doi.org/ 10.1371/journal.pntd.0008035
ISSN: 1935-2735
Appears in Collections:Articles publicats en revistes (ISGlobal)

Files in This Item:
File Description SizeFormat 
Alonso-Padilla_J_PLoS_Negl_Trop_Dis_2020.pdf443.31 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons